Linezolid resistance in a clinical isolate of Staphylococcus aureus

Lancet

Volumn 358, Issue 9277, 2001, Pages 207-208

  Tsiodras, Sotirios ^a,c   Gold, Howard S ^a,c   Sakoulas, George ^a,c   Eliopoulos, George M ^a,c   Wennersten, Christine ^a   Venkataraman, Lata ^a   Moellering Jr , Robert C ^a,c   Ferraro, Mary Jane ^b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXAZOLIDINONE DERIVATIVE; TETRACYCLINE;

AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PERITONITIS; BACTERIUM ISOLATE; CASE REPORT; DRUG SENSITIVITY; ENTEROCOCCUS; HUMAN; INFECTION CONTROL; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NUCLEOTIDE SEQUENCE; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

EID: 0035928419     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05410-1     Document Type: Article

References (5)

1. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
2. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA
3. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
4. Rapid slide latex agglutination test for detection of methicillin resistance in Staphylococcus aureus
5. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action